跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 121,166 条关于
“RET fusion-positive thyroid cancer”
全部
121,166
临床试验
95,581
药物
3,293
机构
1,261
资讯
21,031
去年
CStone Pharmaceuticals Receives NMPA Approval for Local Manufacturing of RET Inhibitor GAVRETO in China
5个月前
Final ARROW Study Data Shows Pralsetinib Achieves 70% Response Rate in RET+ NSCLC with Durable Survival Outcomes
7个月前
RET Fusion Targeted Therapies Market Projected for Significant Growth Through 2034
去年
FDA Grants Full Approval to Selpercatinib for RET-Mutant Medullary Thyroid Cancer
去年
FDA Approves Lilly's Retevmo as First Targeted Therapy for RET-Positive Lung and Thyroid Cancers
3个月前
Kelun-Biotech's Lunbotinib Fumarate Shows Promising Phase II Results in RET Fusion-Positive NSCLC
7个月前
Lilly's Retevmo Shows Significant Event-Free Survival Benefit in Early-Stage RET Fusion-Positive Lung Cancer
去年
Selpercatinib Shows Sustained Long-term Efficacy in RET Fusion-Positive NSCLC Patients
12个月前
Kelun-Biotech's Next-Generation RET Inhibitor A400/EP0031 Receives NDA Acceptance in China for NSCLC Treatment
去年
SY-5007 Demonstrates Promising Efficacy in RET-Altered Solid Tumors: Phase 1 Trial Results
第 1 页，共 2104 页
上一页
下一页
